Pharma IQ's IP Strategies for Crystalline Forms Report

LONDON, August 8, 2011 /PRNewswire/ --

Pharma IQ has just published the results of an industry wide IP Crystals Survey, conducted recently among 6,000 patent specialist with over 65 % of those surveyed  directly responsible for application drafting.

The results showed that that almost 85.3 per cent of firms are currently involved in fewer than four litigation cases, while only 14.3 per cent have a greater number of court proceedings to handle. It was also found that many drug companies are using external counsels.

With regard to the most important word regions, Europe was named an important geographical region to the patent strategies of 83.3 per cent, while the US was found to be a main area of interest for 33.3 per cent of respondents. Asia was cited as a priority by just 16.7 per cent of participants in the study.

The survey was created as a part of the pre-conference research for 7th Annual Developing IP Strategies for Crystalline Forms, taking place 24 - 26 October, 2011 in London.

The results helped to shape the agenda and final speaker line-up which features Bertrand Gellie, Director from European Patent Office explaining the EPO perspective on drafting and designing a robust and meaningful crystalline form patent and Paul Fehlner, Global Head, Pharma Intellectual Property from Novartis leading a sessionUnravelling Multinational Approaches to Avoid Exploitation: Strategies For Obtaining A Preliminary Injunction.

Other important topics expressed by survey respondents that will be discussed at the event include:

• Enforcing and protecting your polymorph patent with insights and experiences from James Horgan, Assistant Counsel, Merck
  
• Unravelling multinational approaches to avoid exploitation: strategies for obtaining a preliminary injunction (Paul Fehlner, Global Head, Pharma Intellectual Property, Novartis)
  
• Update On The Community/EU Patent And Unified Litigation System (Bo Hammer Jensen, Senior Patent Counsel, Novozymes)
  
• Roundtable discussion led by Chris Hayes, Senior Advisor Intellectual Property Rights - Launched Products from Lundbeck and Mandar Kodgule, Head Intellectual Property and Strategic Planning from Wockhardt

To access the full survey report or to find out more about 7th Annual Developing IP Strategies for Crystalline Forms please visit the website  http://www.ipcrys.com, email  [email protected] or call +44(0)2073689300.

Media contact: Joanna, +44(0)20-7368-9807, [email protected]  - Please contact for more information or images.

Press are invited to attend this important industry forum, if you would like to a complimentary press pass please email Joanna Checinska ([email protected])

SOURCE Pharma IQ